WHO Releases New Guidelines on GLP-1 Drugs for Obesity Treatment
The World Health Organization (WHO) has officially shared new guidelines regarding the use of GLP-1 drugs for treating obesity. These medications, which mimic a natural hormone that helps regulate appetite, are most commonly used for managing type 2 diabetes, but their role in weight loss is gaining attention.
On December 1, WHO emphasized the urgent need to tackle the global problem of obesity through these new recommendations. Currently, obesity affects over one billion people worldwide and is linked to approximately 3.7 million deaths annually. Experts predict that the number of individuals with obesity could double by 2030.
Earlier this year, GLP-1 drugs were included in WHO’s Essential Medicines List for high-risk diabetes patients. Now, the new guidelines provide two key recommendations for treating obesity.
Firstly, the guidelines state that adults, excluding pregnant women, can use GLP-1 therapies for long-term treatment of obesity. While the drugs have shown effectiveness in improving health outcomes related to obesity, the recommendation is conditional due to limited long-term data and concerns about safety, cost, and health system readiness.
Dr. Tedros Adhanom Ghebreyesus, WHO’s director-general, noted that “our new guidance recognizes that obesity is a chronic disease that can be managed with comprehensive care.”
Secondly, the guidelines advocate for offering intensive behavioral interventions, such as healthy eating, regular exercise, and support from healthcare professionals, to adults taking GLP-1 medications. This approach is intended to provide a holistic strategy for managing obesity.
The financial burden of obesity is also concerning, with costs expected to reach $3 trillion annually by 2030. WHO’s guidelines aim to address the rising healthcare expenses associated with obesity and its complications. They stress the importance of equitable access to GLP-1 treatments, warning that without action, existing health disparities may worsen.
The guidelines call on the global community to develop strategies to expand access to these drugs, including pooled procurement and tiered pricing.
Despite advances in the production of GLP-1 therapies, WHO predicts that by 2030, only a small fraction, less than 10%, of eligible individuals will have access to these treatments.
In summary, while GLP-1 therapies are a promising new option for addressing obesity, WHO emphasizes that they should be part of a broader strategy that includes creating healthier environments and ensuring ongoing access to healthcare services.
